oral tirzepatide efficacy and Injectable Semaglutide Correlated with Greatest Weight Loss Among GLP-1 Medications Oral Tirzepatide: What the Research

Science 334, 17311734

Glucagon receptor agonism in metabolic disease: revisiting an old target

The potential of semaglutide and similar medications to aid in reducing alcohol consumption opens new avenues for treating alcohol use disorder

Half-Life and Route GHRP-2 is a small peptide and, like most peptides, is not orally bioavailable in any efficient way because it is degraded in the gastrointestinal tract which is why parenteral (typically subcutaneous) administration dominates the research literature, and why intranasal delivery was explored in some early studies

Increasing evidence suggests that GLP-1 RAs may provide beneficial kidney effects in individuals with T2DM and CKD, as shown in CVOTs

While no official contraindication exists, the combination requires careful consideration